09:12 AM EDT, 08/20/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) said Wednesday that the TSX accepted its normal course issuer bid.
Under the NCIB, Knight can purchase up to 3 million shares, or 3% of its issued and outstanding shares, over the next 12 months starting Friday and ending Aug. 21, 2026.
Knight's share price gained 1.4% on Tuesday to $6.39 on the TSX.